RNS Number:7773B
Cross Shore Acquisition Corporation
08 August 2007




Cross Shore Acquisition Corporation

8 August 2007


THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE
UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH
  AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
              VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.


                              New Contract Award


Cross Shore Acquisition Corporation announces today that it has been informed 
by ReSearch Pharmaceutical Services, Inc.("RPS") that RPS has signed a new 
contract with a major pharmaceutical company. RPS currently estimates that it
will generate revenue under this contract of approximately $40 million over the
next three years.



ENQUIRIES:

Cross Shore                                         +1 843 597 4760
Dennis Smith

Arbuthnot Securities Limited                        +44 207 012 2000
Nominated Adviser
James Steel / Guy Blakeney


This announcement does not constitute, or form part of, an offer or an
invitation to purchase any securities.

This announcement is not for distribution into the United States, Canada, Japan,
Australia, the Republic of Ireland or the Republic of South Africa or any other
jurisdiction where its distribution would constitute a violation of the relevant
laws of such jurisdiction. Neither Cross Shore Shares nor the Cross Shore
Warrants have been registered under the United States Securities Act of 1933, as
amended, or under the applicable securities laws Canada, Japan, Australia, the
Republic of Ireland or the Republic of South Africa. Accordingly (subject to
certain exceptions), neither the Cross Shore Shares nor the Cross Shore Warrants
may, directly or indirectly, be offered or sold within the United States,
Canada, Japan, Australia, the Republic of Ireland or the Republic of South
Africa or to or by any national, resident or citizen of such countries. The
distribution of the Readmission Document in other jurisdictions may be
restricted by law and therefore persons into whose possession the Readmission
Document comes should inform themselves about and observe any such restrictions.
Any failure to comply with these restrictions may constitute a violation of the
securities law of any such jurisdictions.

Arbuthnot Securities Limited, which is authorised and regulated in the United
Kingdom by the Financial Services Authority, is acting as nominated adviser and
UK broker to the Company in connection with Re-admission. Its responsibilities
as the Company's nominated adviser under the AIM Rules are owed solely to the
London Stock Exchange and are not owed to the Company or to any Director or
Proposed Director or to any other person.

Arbuthnot Securities Limited is acting exclusively for the Company and for no
one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their clients or for providing advice in
relation to the contents of this announcement or the Re-admission. No
representation or warranty, express or implied, is made by Arbuthnot Securities
Limited as to the contents of this announcement. The information contained in
this announcement is not intended to inform or be relied upon by any subsequent
purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and
accordingly no duty of care is accepted in relation to them.

The Directors and Proposed Directors of Cross Shore Acquisition Corporation
accept responsibility, individually and collectively, for the information
contained in this announcement and for compliance with the AIM Rules. To the
best of the knowledge and belief of the Directors and Proposed Directors, who
have taken all reasonable care to ensure that such is the case, the information
contained in this announcement is in accordance with the facts and does not omit
anything likely to affect the import of such information.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
CNTUWABRBARWRAR
Cross Shore Acquisition (LSE:CSE)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Cross Shore Acquisition Charts.
Cross Shore Acquisition (LSE:CSE)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Cross Shore Acquisition Charts.